Enbrel and Humira to continue dominance of rheumatoid arthritis market to 2018
Despite stiff competition from newer biologics and biosimilars, physicians expect Enbrel (etanercept) from Amgen (Nasdaq: AMGN) and Humira (adalimumab) from AbbVie (NYSE: ABBV) to continue their dominance of the rheumatoid arthritis market, according to the RA Perceptions survey from market research specialist Research Partnership.
The results of the survey indicate that the current market leaders Humira and Enbrel will continue to lead the market, and be used to treat more than a third of rheumatoid arthritis patients in three years’ time. The anti-TNF segment is predicted to experience a strong downturn, specifically a 19% loss in share, in the same period.
Biologics with novel mechanisms of action such as RoActemra (tocilizumab) from Roche (SIX: ROG) are expected to outperform the overall EU biologics market with 15% growth over the next three years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze